Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31487941 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPK1OPRD1TSHR | |
| SCHEMBL6896443 | 0.78 | OPRD1 (0.46) | OPRD1 | |
| SCHEMBL22508643 | 0.78 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPK1TSHRMAPT | |
| SCHEMBL390902 | 0.77 | CCR4 (0.40) | OPRD1 | |
| SCHEMBL7509729 | 0.73 | CA2 (0.41) | — | |
| SCHEMBL28297048 | 0.73 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPK1TSHRMAPT | |
| SCHEMBL3175779 | 0.71 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPK1TSHRMAPT | |
| SCHEMBL27708565 | 0.71 | AGTR2 (0.31) | — | |
| SCHEMBL22010263 | 0.70 | LMNA (0.42) | ALDH1A1LMNAMAPK1OPRD1TSHR | |
| SCHEMBL21800159 | 0.68 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPK1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462555-A | Sulfonamide compound and application thereof | 上海科技大学 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025031360-A1 | SULFONAMIDE COMPOUND AND USE THEREOF | 上海科技大学 | 2025-02-13 | — | — | WO | disclosed |
| CN-101304992-A | 1, 3-disubstituted indole derivatives for use as PPAR modulators | PLEXXIKON INC (US) | 2008-11-12 | — | — | CN | disclosed |
| EP-1943245-A2 | 1,3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
| EP-1194430-A1 | NOVEL PROCESS | NOVO NORDISK A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002410-A1 | NOVEL PROCESS | NOVO NORDISK A/S (DK) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PPARG, PPARA, PPARD | ALDH1A1 277/4885LMNA 3043/4885MAPK1 1223/4885 |
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | ALDH1A1 267/4885LMNA 4566/4885MAPK1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.